Abstract:| https://dx.doi.org/10.21037/hbsn-21-392 Up to know, product information for COVID-19 mRNA vaccines do not include their use in patients receiving immunosuppressive medication, since they were not included in trials (1) . For the BNT162b2 mRNA vaccine, one case of otherwise totally asymptomatic elevations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (GGT) serum concentrations in a liver transplant recipient has been reported after the first injection (2). In the present retrospective study, we present safety outcomes of COVID-19 vaccinations in 56 liver transplant patients from two Chinese centers vaccinated with the domestic PiCoVacc, BBIBP-CorV and ZF2001 vaccines. Thirty vaccinated physicians from the Hepatopancreatobiliary Center of Beijing Tsinghua Changgung Hospital served as control, from which 1 participant received an Ad5-nCoV vaccine. The study deadline was 2021-10-31. The observation period for adverse reactions, such as muscle pain and fatigue was 1 week, while for laboratory examinations such as liver function the follow-up period was 1 month. PiCoVacc and BBIBP-CorV are both inactivated COVID-19 virus vaccines with a two-dose schedule and a spacing of 3 to 4 weeks, while ZF2001 is a recombinant tandem-repeat dimeric receptor-binding domain (RBD)based protein subunit vaccine with an application of three doses over a period of 2 months. Ad5-nCoV is a viral vector vaccine applied as a single injection. Table 1 shows the basic characteristics of the 86 participants. Adverse reactions in the liver transplant and control groups were fatigue (4, 7.1% vs. 1, 3.3%), local pain (9, 16.1% vs. 6, 20.0%), cough (1, 1.8% vs. 0), rhinorrhea (1, 1.8% vs. 0) and drowsiness (0 vs. 4, 13.3%), respectively. All adverse reactions were mild. Fifty-four participants had normal liver function tests within 1 month before and after vaccination. A 37-year-old patient, 70 months after transplantation due to a primary liver cancer who was receiving an antirejection regimen of sirolimus + mycophenolate mofetil (MMF), had liver enzyme values of ALT 72.0 U/L, AST 37.6 U/L, total bilirubin (TBIL) 13.7 μmol/L, ALP 80.0 U/L and GGT 58.3 U/L before and ALT 68.3 U/L, AST 37.7 U/L, TBIL 11.0 μmol/L, ALP 96.0 U/L and GGT 62.2 U/L after vaccination. The condition was considered to be related to the graft fatty liver and the liver function changes were not significant before and after vaccination. The second case was a 46-year-old patient with hepatic alveolar echinococcosis 30.7 months after transplantation and an anti-rejection regimen of tacrolimus + MMF. Liver enzyme values were ALT 22 U/L, AST 29 U/L, TBIL 12.4 μmol/L, ALP 134 U/L, GGT 44 U/L before and ALT 19 U/L, AST 25 U/L, TBIL 11 μmol/L, ALP 106 U/L and GGT 41 U/L after vaccination. The patient underwent a choledochojejunostomy, because of a narrow biliary anastomosis. Since there was no stenosis after the choledochojejunostomy, this abnormal ALP may be related to the state of bilioenteroanastomosis. Two of the vaccines in the present study were inactivated viruses, which are only recommended for solid organ transplant recipients after careful risk benefit assessment, Letter to the Editor

Acute hepatitis following mRNA BNT162b2 COVID-19 vaccination

Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination

Inspiration to Mrna-Based COVID-19 Vaccination: Serious Adverse Case Reports with Hepatitis B Vaccine in Real-World

Deep vein thrombosis and acute hepatitis after ChAdOx1 nCov-19 vaccination in a Charcot-Marie-Tooth patient: a case report

Necrotizing pancreatitis, microangiopathic hemolytic anemia and thrombocytopenia following the second dose of Pfizer/BioNTech COVID-19 mRNA vaccine

[Multiple microthromboses with autoimmune hemolytic anemia after BNT162b2 mRNA vaccination]

Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore

Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines

New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination

Adverse Events Following BNT162b2 mRNA COVID-19 Vaccine Immunization among Healthcare Workers in a Tertiary Hospital in Johor, Malaysia

Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

ERAP-1 and ERAP-2 variants in Liver injury following COVID-19 mRNA Vaccination: A US Multicenter Study

Safety Analysis of COVID-19 Vaccines in Liver Transplant Recipients: a Two-Center Study.

Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination

Syncopes, paresis and loss of vision after COVID-19 mRNA-based vaccination and SARS-CoV-2 infection

Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination

Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases

Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series